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Huntington’s disease (HD) is a fatal neurodegenerative disorder of genetic origin with no known therapeutic intervention that can slow or halt
disease progression. Transgenic murine models of HD have significantly improved the ability to assess potential therapeutic strategies. The R6/2
murine model of HD, which recapitulates many aspects of human HD, has been used extensively in pre-clinical HD therapeutic treatment trials. Of
several potential therapeutic candidates, both minocycline and coenzyme Q10 (CoQ10) have been demonstrated to provide significant improvement
in the R6/2 mouse. Given the specific cellular targets of each compound, and the broad array of abnormalities thought to underlie HD, we sought
to assess the effects of combined minocycline and CoQ10 treatment in the R6/2 mouse. Combined minocycline and CoQ10 therapy provided an
enhanced beneficial effect, ameliorating behavioral and neuropathological alterations in the R6/2 mouse. Minocycline and CoQ10 treatment
significantly extended survival and improved rotarod performance to a greater degree than either minocycline or CoQ10 alone. In addition,
combined minocycline and CoQ10 treatment attenuated gross brain atrophy, striatal neuron atrophy, and huntingtin aggregation in the R6/2 mice
relative to individual treatment. These data suggest that combined minocycline and CoQ10 treatment may offer therapeutic benefit to patients
suffering from HD.
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Huntington’s disease (HD) is a devastating neurodegener-
ative disorder caused by an autosomal dominant genetic defect
resulting in the expansion of a polyglutamine region in the
huntingtin protein. Clinically, HD is characterized by the mid-
life onset of progressive chorea, cognitive decline, and
psychiatric disturbance, with significant involvement of the
basal ganglia [1]. Neuropathological alterations within the0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: rjferr@bu.edu (R.J. Ferrante).caudate and putamen consist of marked selective neuronal loss
and increased astrogliosis and are the most prominent
neuropathological changes that occur in HD [1–3].
The specific genetic defect responsible for HD is an
expanded CAG trinucleotide sequence within the coding
region of the IT 15 gene [4], which encodes the protein
huntingtin (htt). Both normal and mutant alleles are present in
heterozygotic HD patients, though a toxic gain-of-function
attributed to the mutant htt and a concomitant loss of normal htt
are both thought to play roles in HD pathogenesis [5,6]. While
the exact mechanism responsible for the selective striatal
neurodegeneration in HD is unknown, aberrant protein–protein
interactions have been suggested to play a central role.
Cleavage of the mutant htt releases toxic N-terminal fragments,1762 (2006) 373 – 380
http://www
Fig. 1. The effects of minocycline and CoQ10 treatments alone or in
combination on survival in R6/2 HD transgenic mice. Oral administration of
CoQ10 (0.2%; open triangle, q) and i.p. administration of 5 mg/kg/day
minocycline (open square, g) in R6/2 HD mice significantly improved survival
by 14.6% and 11.2%, respectively, compared to the unsupplemented R6/2 HD
mice (closed square, n). The combined therapy of minocycline and CoQ10
(open circle, >) increased survival by 18.2% compared to the unsupplemented
R6/2 HD mice.
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aggregates containing mutant htt. Monomeric and oligomeric
assemblies of mutant htt, as well as nuclear mutant htt
aggregates, are thought to lead to transcription dysregulation
[7,8], resulting in subsequent altered signal cascades involved
in oxidative stress, mitochondrial dysfunction, apoptosis,
energy metabolism, and excitotoxicity, all of which may
promote the neuropathological sequela [9]. At present, there
is no known effective therapeutic treatment or cure for HD.
Recapitulation of the features of human HD has made the
R6/2 transgenic mouse an ideal model for pre-clinical
therapeutic trials for HD [9,10]. Indeed, success in such pre-
clinical trials have lead to several human clinical trials,
including creatine, cysteamine, phenylbutyrate, remacemide,
riluzole, minocycline and CoQ10 [11]. Of these compounds,
both minocycline and CoQ10 have shown significant improve-
ment in the R6/2 phenotype [12–14]. The semisynthetic
tetracycline minocycline has been used successfully for over
30 years in humans as an antibiotic [15]. The scientific
rationale for using minocycline arises from its anti-apoptotic
effect. Minocycline is a second-generation tetracycline capable
of inhibiting caspase-1 and -3 activities, expression levels, and
the release of apoptogenic factors from mitochondria, as well
as caspase independent neuronal cell death pathways
[12,14,16,17]. Minocycline has demonstrated broad neuropro-
tection in various models of neurodegeneration, including
multiple sclerosis, brain trauma, spinal cord injury, amyo-
trophic lateral sclerosis, Parkinson’s disease, and HD
[5,14,16,18–20]. While the beneficial role of minocycline is
well established in neurological disorders, contrary evidence
exists relative to minocycline treatment in HD [see 14
compared to 21], with significant differences in methodologies
between studies that may account for the discrepancy [22].
Although the mechanism by which minocycline provides
neuroprotection in such a broad spectrum of neurodegenerative
contexts is not clearly understood, it is thought to involve
inhibition of both innate and adaptive immune activity [23], as
well as attenuating the disruption of mitochondrial function,
preventing the release of cytochrome C, and inhibiting the
apoptotic cascade [14,16].
CoQ10 is a lipid-soluble benzoquinone derivative structur-
ally similar to vitamin K. It resides in the inner mitochondrial
membrane and is essential for Complexes I and II electron
transfer activities during oxidative phosphorylation [24].
CoQ10 plays a vital role in ATP production (oxidative
phosphorylation). CoQ10 also has membrane-stabilizing prop-
erties and acts as an antioxidant in both mitochondrial and lipid
membranes [24]. The neuroprotective effects of CoQ10 have
been reported in multiple models of neurodegeneration [24],
including HD [9,13]. Treatment with CoQ10 in HD patients has
showed a trend towards slowing in total functional capacity
decline over 30 months; however, the study was not powered to
be able to detect an effect of this magnitude. Nonetheless, there
was a significant effect in slowing functional decline and
significant beneficial effects on several measures of cognitive
function, including the Stroop color naming and word reading
tasks, and the Brief Test of Frequency [25].While both CoQ10 and minocycline have demonstrated
neuroprotection in the R6/2 murine model of HD, the additive
effects of combined administration of minocycline and CoQ10
have not been explored. In the present experiments, we
examined whether administration of combined minocycline
and CoQ10 exerts enhanced beneficial effects in the R6/2
mouse model of HD.
2. Materials and methods
2.1. Animals
Transgenic R6/2 male mice from a stable colony maintained in our
laboratory for over 7 years were bred with females from their background strain
(B6 CBAFI/J). The offspring were genotyped by PCR assay of DNA obtained
from tail tissue. In all, a total of 120 mice were used in the following analyses.
To ensure homogeneity of experimental cohorts, mice were placed into testing
groups using a previously standardized protocol [26]. Mice were randomized
from 26 litters all within 4 days of the same age from the same Ff_ generation.
There can be great variability in phenotype presentation in R6/2 mice, which is
dependent on CAG repeat size and this may reduce significance of outcome
measures [10]. All mice used in this study had CAG repeats in the range of
148–153, with corresponding base pairs of 500–550, as determined by PCR.
Mice that had altered base-paired banding identified from PCR analysis were
excluded from the study. Since we have not observed gender differences in
survival in the R6/2 transgenic HD mouse model [10], female mice were used
in the experimental paradigms. All mice were weighed at 20 days of age prior
to placement and equally distributed according to weight within each cohort.
Mice under 7 g at this time point were not used in the experiments. Enrichment
conditions were not applied to any cages because of its effect on improving
phenotype in R6/2 mice. Mice were weaned into their study groups and
treatments began at 26 days (n =10/group). The study groups included:
unsupplemented, given saline by intraperitoneal (i.p.) injection (0.9%),
minocycline (Sigma, MO),given by i.p. injection dissolved in saline (5 mg/
kg/day) and made freshly daily, CoQ10 (0.2%, Chemco Industries Inc, CA)
supplemented in the chow, and a combination of minocycline and CoQ10. The
mice were handled under the same conditions by one investigator at the same
day and time. Mice were identified by a randomly assigned code so that the
studies were performed blind as to the genetic identity of the mice. The mice
were housed five in each cage under standard conditions with ad libitum access
to food and water and assessed according to specific criteria. All animal
experiments were performed in accordance with the NIH Guide for the Care
and Use of Laboratory Animals and were approved by both the Veterans
Administration and Boston University Animal Care Committees.
Fig. 2. The effects of treatment with minocycline and CoQ10 alone or in
combination on rotorod performance in R6/2 transgenic HD mice. All three
treatment paradigms tested: minocycline (open square,g); CoQ10 (open triangle,
q) and the combination of minocycline and CoQ10 (open circle,>) significantly
improved motor performance starting at 5 weeks and continuing throughout the
entire measured period in contrast to unsupplemented R6/2 HD mice (closed
square, n). Wild type littermate mice are shown as closed circles (?).
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Mice (N = 40) were observed twice daily. Criteria for euthanasia was the
point in time when R6/2 mice could no longer right themselves after 30 s when
placed on their side. This was confirmed by two separate observers and
considered the time of death. A limited number of deaths occurred overnight
and were recorded the following morning.
2.3. Motor performance and body weight assessment
The rotarod (Columbus Instruments, Columbus, OH) was used to assess
R6/2 motor performance. Beginning at 28 days of age, R6/2 mice (N = 40)
and wild type littermate control mice (N = 10) were evaluated weekly, then
twice weekly from 63 days, on the same day(s) and time. All mice were
familiarized with the rotarod testing apparatus over 2 days prior to testing.
During testing, mice were placed on the rod with a constant rotating speed of
16 rpm for three consecutive sessions per day no longer than 60s, and then
returned to the home cage. The average length of time remaining on the
rotarod was taken as a measure of competency, with a maximum score of 60s.
Body weights were obtained twice a week at the same day and time during
treatment.Fig. 3. The effects of treatment with minocycline and CoQ10 alone or in combination
CoQ10 (open triangle, q) resulted in significant improvement of body weight loss th
(closed square, n). In contrast, daily i.p. administration of 5 mg/kg/day minocyclin
loss, while the combination of minocycline and CoQ1010 (open circle, >) did resu2.4. Histological evaluation
Mice (R6/2 mice=40; wild type=10) were deeply anesthetized and
transcardially perfused with 4% buffered paraformaldehyde at 90 days, with
care to avoid the introduction of any physical or perfusion artifact. The
perfusions and brain removal from the skull were completed by one
investigator (SJD), post-fixed in the perfusate for 2 h, rinsed in buffer and
then cryoprotected in a graded series of 10 and 20% glycerol/2% dimethyl
sulfoxide (DMSO). Frozen serial sections were cut at 50 Am, stored in six well
plates, and stained for Nissl substance using cresyl violet. Immunocytochemical
detection of mutant huntingtin (htt) and CD-11b (Mac-1, a marker of microglia)
was performed. Sections were rinsed in tris-buffered saline with Tween 20
(TBS-T) containing 10% normal goat serum for 1 h. Sections were then
incubated overnight in TBS-T with 0.1% sodium azide and mouse anti-
huntingtin, recognizing the N-terminal aspect of human and murine huntingtin
(1:500, Chemicon, Temecula, CA) or mouse anti-Mac-1 (1:200, Serotec,
Raleigh, NC). Sections were rinsed three times in TBS-T, followed by a 2- to 3-
h incubation in TBS-T containing a goat anti-mouse peroxidase-conjugated
secondary antibody to detect htt or Mac-1. Sections were then rinsed three
times in TBS-T. Antibody complexes were visualized using diaminobenzidine.
Preabsorbtion with excess target protein, or omission of either primary or
secondary antibody, was used to demonstrate antibody specificity and
background generated from the detection assay. Tissue sections were examined
using a Nikon Eclipse E800 microscope with a Spot RT digital camera.
2.5. Stereology
Serial-cut coronal tissue sections (every 3rd section) from the rostral
segment of the neostriatum to the level of the anterior commissure (interaural
5.34 mm/bregma 1.54 mm to interaural 3.7 mm/bregma 0.10 mm) [27] were
used for gross brain and striatal neuron area analyses. Gross brain volume was
measured using Neurolucida Stereo Investigator software (Microbrightfield,
Colchester, VT). Striatal neuron areas were analyzed by microscopic video
capture using a Windows-based image analysis system for area measurement
(Optimas, Bioscan Incorporated, Edmonds, WA). The software automatically
identifies and measures profiles. All computer-identified cell profiles were
manually verified.
2.6. Statistics
Data are expressed as a meanTS.E.M. For interval scale data, comparisons
were made with one-way ANOVA using Statview (SAS, Cary, NC), followed byon body weight in R6/2 transgenic HD mice. Dietary supplementation of 0.2%
roughout the 16-week trial in comparison to the unsupplemented R6/2 HD mice
e alone (open square, g) had no significant effect on ameliorating body weight
lt in significant body weight improvement.
Fig. 4. Effects of minocycline, CoQ10 , and the combination treatment on gross atrophy in R6/2 HD mice at 90 days of age. Photomicrographs of coronal serial step
sections from the rostral neostriatum through the level of the anterior commissure in a wild-type (WT) littermate mouse (A1–A5), an unsupplemented R6/2 HD
mouse (B1–B5), a 5 mg/kg/day minocycline-treated R6/2 HD mouse (C1–C5), a 0.2% CoQ1010-treated R6/2 HD mouse (D1–D5), and a combined minocycline/
CoQ1010-treated R6/2 HD mouse (E1–E5). In comparison to the WT mouse, marked gross atrophy and enlarged lateral ventricles are present in the unsupplemented
transgenic R6/2 HD mouse. Gross brain atrophy and ventricular enlargement are reduced in the minocycline, CoQ10, or combined minocycline and CoQ10
supplemented R6/2 HD mice, compared to the unsupplemented R6/2 HD mouse. Magnification in A5 equals 2 mm.
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analyzed using the product limitmethod ofKaplan andMeier, and survival curves
were compared by the logrank test using Prism (GraphPad, San Diego, CA).3. Results
The effect of minocycline or CoQ10, alone or in
combination, on R6/2 survival is shown in Fig. 1. All
treatment paradigms significantly extended survival in the
R6/2 murine model of HD. Daily minocycline administration
(5 mg/kg, i.p.) or dietary supplementation in the chow with
0.2% CoQ10 significantly increased the mean R6/2 survival
by 11.2% and 14.6% (minocycline: 110.1T1.3 days; CoQ10:
113.9T0.8 days) respectively, when compared to unsupple-Table 1
Brain volumes and striatal neuron area in treated and untreated R6/2 mice
Wild type
littermate mice
R6/2 mice
untreated
R6
m
Brain volume 4.19T0.35107 Am3 3.14T0.42107 Am3* 3.7
Striatal neuron area 135.1T11.2107 Am3 54.2T16.8107 Am3* 92
* P <0.01, compared to wild type littermate mice.
. P <0.01, compared to R6/2 mice untreated.mented control R6/2 mice (unsupplemented: 98.8T0.8 days).
Combined administration of both minocycline (5 mg/kp, i.p.)
and dietary CoQ10 significantly increased R6/2 survival by
18.2% (minocycline/CoQ10: 116.8T1.0; P <0.0001). While
the combined administration of minocycline and CoQ10 had
a modest additive effect on R6/2 survival, the combined
treatment of daily minocycline and CoQ10 was significantly
more effective than either minocycline (P <0.0002) or
CoQ10 (P <0.02) alone.
The effect of minocycline or CoQ10, alone or in combina-
tion, on motor performance on the rotarod is shown in Fig. 2.
As previously reported, there was a significant reduction in
motor performance on the rotarod between R6/2 mice and
wild type littermates [10]. Daily treatment with minocycline (5/2 mice
inocycline-treated
R6/2 mice
CoQ10-treated
R6/2 mice minocycline/
CoQ10-treated
2T0.35107 Am3. 4.03T0.28107 Am3. 3.96T0.26107 Am3.
.9T14.2107 Am3. 107.6T14.6107 Am3. 105.2T15.3107 Am3.
Fig. 5. Effects of minocycline and the combination of minocycline and CoQ10 on striatal neuronal atrophy in R6/2 HD mice at 90 days of age. Representative
photomicrographs of Nissl-stained tissue sections from the dorso-ventral aspect of the striatum from a littermate wild type mouse (A), an unsupplemented R6/2 HD
mouse (B), a minocycline (5 mg/kg/day)-treated R6/2 HD mouse (C), and a combined minocycline (5 mg/kg/day)/CoQ1010 (0.2%)-treated R6/2 HD mouse (D) at 90
days. Compared to the control wild-type littermate (A), there is marked neuronal atrophy with small angulated neurons in the unsupplemented mouse (B), with
relative preservation of neuronal size in the minocycline and minocycline/CoQ1010-treated R6/2 HD mice (C and D). Magnification bar in A equals 25 Am.
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compared to the unsupplemented R6/2 mice starting at 5
weeks of age through 14 weeks (F(49,657), 19.15; P <0.02).
Similarly, daily dietary supplementation with CoQ10 signifi-
cantly improved rotarod performance compared to the
unsupplemented R6/2 mice from 5 weeks of age through 14
weeks (F(49,657), 14.27; P <0.01). Combined daily adminis-
tration of minocycline (5 mg/kg, i.p.) and dietary supplemen-
tation with CoQ10 showed the most pronounced significant
improvement in rotarod performance compared to the unsup-
plemented R6/2 mice from 5 weeks of age through 14 weeks
(F(49,657), 12.85; P <0.001).
The effect of minocycline, CoQ10, or combined minocycline
and CoQ10, on body weight is shown in Fig. 3. While daily
administration of minocycline (5 mg/kg, i.p.) had no effect on
body weight when compared to the unsupplemented R6/2 mice
at any time point examined, daily dietary supplementation with
CoQ10 significantly improved body weight compared to the
unsupplemented R6/2 mice starting at 6 weeks of age through
15 weeks of age (F(43,866), 15.62; P <0.001), as previously
reported [13]. In addition, combined treatment with minocy-
cline (5 mg/kg, i.p.) and dietary supplementation with CoQ10
also showed significant improvement in body weight from 13
weeks of age through 16 weeks (F(43,866), 20.12; P <0.02 ).
The improvement in body weight pursuant to the combination
therapy, however, is likely a consequence of the CoQ10
treatment.
Examination of neuropathological sequela in R6/2 mice
treated with minocycline or CoQ10, alone or in combination,Fig. 6. The effect of minocycline , CoQ10, and combined minocyline/CoQ10 treatme
of age. Representative photomicrographs from the dorsomedial striatum from an unt
CoQ10, (0.2%) treated R6/2 mouse (C), and a minocycline/CoQ10 treated R6/2 mous
in the striatum of unsupplemented R6/2 mice (A). Minocycline (5 mg/kg/day) treatm
while CoQ10 treatment alone markedly reduced htt-immunopositive aggregates w
minocycline/CoQ10 treated R6/2 mice also reduced htt-immunopositive aggregationrevealed significant neuroprotection in each of the treatment
groups compared to unsupplemented R6/2 mice. R6/2 mice
demonstrate significant brain atrophy and ventricular hyper-
trophy along with a flattening of the medial aspect of the
striatum when compared to wild-type control mice (Fig. 4), as
previously reported [10]. Further examination of each treat-
ment group showed a marked attenuation of both gross brain
atrophy and ventricular hypertrophy when compared to the
unsupplemented R6/2 mice (Table 1). At 90 days of age, gross
brain volume from the rostral pole of the frontal cortex to the
anterior commissure in unsupplemented R6/2 mice was
significantly less than wild type littermate control mice
(33.4%; P <0.01). In contrast, minocycline, CoQ10, and
combined minocycline/CoQ10 treatment significantly reduced
brain atrophy in R6/2 mice by 18.5%, 28.3%, and 26.1%,
respectively (F(4,50), 22.36; P <0.01).
Further microscopic analysis of the dorso-medial aspect of
the striatum at the level of the crossing of the anterior
commissure, at the ventral border of the corpus callosum, in
unsupplemented R6/2 mice revealed pronounced neuron
atrophy with small, angular neurons, when compared with
wild-type littermate mice (Fig. 5). Treatment with minocy-
cline or CoQ10, alone or in combination, markedly attenuated
striatal neuronal atrophy in comparison to untreated R6/2
mice (F(4,50), 16.34, P <0.01) (Table 1). As previously
reported [12], minocycline had no effect on striatal htt
aggregation (Fig. 6), while CoQ10 and the combined
minocycline/CoQ10 treatment reduced htt aggregation within
the striatum in the R6/2 mouse. This latter effect is mostnt on huntingtin aggregate formation in the neostriatum of R6/2 mice at 90 days
reated R6/2 mouse (A), a minocycline (5 mg/kg/day) treated R6/2 mouse (B), a
e at 90 days of age (D). Huntingtin (htt) immunopositive aggregates are present
ent had no effect on htt-immunopositive aggregation within the neostriatum (B),
ithin the neostriatum (C), as has been previously reported. The combined
within the striatum (D). Magnification bar in A equals 100 Am.
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alone reduces striatal htt aggregation, as has been previously
demonstrated [13] (Fig. 6).
Mac-1 immunostaining was also performed to assess the
effect of minocycline, CoQ10 and the combined minocycline/
CoQ10 treatment on reducing reactive microglia in R6/2 mice.
Mac-1 immunostained tissue from the dorso-medial aspect of
the striatum revealed an increased reactive microgliosis in
unsupplemented R6/2 mice at 90 days (Fig. 7). QualitativeFig. 7. Effects of minocycline treatment on microglia in R6/2 HD mice at 90
days of age. Representative photomicrographs of Mac1 immunostained tissue
sections from the dorsomedial aspect of the striatum from a wild type littermate
control mouse (A), an unsupplemented R6/2 HD mouse (B), a CoQ10 (0.2%)
treated R6/2 mouse (C), a minocycline (5 mg/kg/day) treated R6/2 HD mouse
(D), and a minocycline/CoQ10 treated R6/2 mouse at 90 days of age (E). In wild
type control brain, microglia are quiescent ovoid cells (arrowheads). Reactive
microglia, rod–shaped cells with prominent coarse arbors (arrows) are increased
in the R6/2 model of HD (B). CoQ10 treatment in R6/2 mice does not alter the
reactive microglia profile (C), while normal appearing microglia without
processes and few reactive microglia are present in minocycline treated (D) and
minocycline/CoQ10 treated (E) R6/2 mice. Magnification bar in A equals 20 Am.examination of CoQ10 treated mice showed no effect on the
microglia response, while administration of minocycline (5
mg/kp, i.p.) and the combined minocycline/CoQ10, attenuated
the microglial response observed in R6/2 mice. Reactive
microglia are prominent aspects of neuropathology observed
in HD patients [28]. Minocycline’s ability to reduce reactive
microglia in the present findings is consistent with previous
reports [29,30].
4. Discussion
Beneficial treatment of neurodegenerative disorders with
multiple pathogenic properties is likely to be achieved only
through the effective administration of polytherapeutic inter-
ventions, with each therapy targeting a specific aspect of the
neurodegenerative phenotype [11,13]. While previous preclin-
ical studies have demonstrated the efficacy of minocycline and
CoQ10 administration alone in models of neurodegeneration,
this is the first report to establish an additive effect of combined
minocycline and CoQ10 in a murine model of HD. This report
provides several examples of statistically significant improve-
ment of the combined treatment over each individual therapy.
Although the combined treatment was not completely additive,
it is in keeping with previously published work [13]. In all
other instances, the benefit of combined therapy was no
different than one or both of the individual therapies.
Minocycline is a semisynthetic tetracycline antibiotic used
to treat bacterial infections and in the management of chronic
conditions, such as acne or arthritis [15]. Minocycline
possesses both antimicrobial and anti-inflammatory proper-
ties, can readily cross the blood–brain barrier, and is well
tolerated in HD patients [31]. In addition, chronic adminis-
tration of the compound has yielded a good clinical safety
record [23]. Minocycline has also been reported to be
efficacious in a broad range of neurological disorders [32],
reducing neuronal loss in several animal models of neuro-
degeneration [5,12,14,16,18,29]. The first example of mino-
cycline-induced neuroprotection was shown in an animal
model of ischemic stroke [29], where minocycline reduced
caspase-1 and inducible nitric oxide synthase (iNOS) mRNA.
Chen and colleagues [12] extended these findings in the R6/
2 murine model of HD, in which minocycline prolonged
survival and delayed the characteristic decline in rotarod
performance associated with these mice [10]. In fact,
minocycline has been shown to inhibit caspase-dependent
and caspase-independent cell death mechanisms [12,14,16].
Furthermore, we have previously demonstrated that minocy-
cline inhibits release of cytochrome c and Smac/Diablo in
isolated mitochondria, indicating that mitochondria are a
direct target of minocycline-mediated neuroprotection
[14,16]. While there has been some disagreement regarding
the beneficial effect of minocyline in the R6/2 mouse [21],
significant differences in methodologies between these
studies may account for the discrepancy [22].
CoQ10 functions as an essential cofactor of the electron
transport chain, shuttling electrons between complexes I and II
to complex III in the mitochondrial electron transport chain
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when reduced to ubiquinol, or through a CoQ10-induced
increase in alpha-tocopherol [24]. Supplementation with
CoQ10 has been demonstrated to significantly increase brain
mitochondrial CoQ10 concentrations [34]. CoQ10 is also well
tolerated in humans, providing significant improvement in
patients with neurological disorders [24,25,35,36]. As with
minocycline, CoQ10 has been reported to reduce neuronal loss
in several animal models of neurodegeneration [24]. In the R6/
2 murine model of HD, CoQ10 significantly extends survival
and delays the typical decline in weight loss and motor
performance as assessed on the rotarod [13]. In addition,
CoQ10 administration significantly attenuates the R6/2 neuro-
pathology, including attenuation of brain weight loss, gross
brain atrophy and ventricular enlargement, and striatal neuron
atrophy [13].
Combined treatment with both minocycline and CoQ10
provides a significantly greater delay in mortality compared to
either agent alone. While this additive effect is not absolute, the
data suggests that each compound may be acting independent-
ly, targeting specific pathogenic abnormalities present in the
R6/2 model of HD in order to achieve neuroprotection.
Alternatively, the lack of an absolute additive effect may result
as a consequence of both agents acting to preserve mitochon-
drial function, in addition to other compound specific
functions. Where these compounds possess overlapping
therapeutic function may result in a less than absolute additive
benefit.
Analysis of weight changes in the R6/2 mice after treatment
with minocycline, CoQ10, or a combination of each compound
provides some insight into the potential mechanism of each
therapy. Weight loss is a prominent feature in HD patients and
R6/2 mice [10,37]. While both CoQ10 and the combined
treatment significantly improved weight loss in the R6/2
mouse, CoQ10 provides significantly greater improvement
relative to the combined treatment. In contrast, minocycline
alone has no effect on R6/2 body weight loss. That
minocycline does not alter body weight in this study is in
keeping with previous reports of minocycline administration in
R6/2 mice [12], while CoQ10’s ability to ameliorate weight loss
in the R6/2 model has been previously reported [13]. Although
the cause of the weight loss observed in R6/2 mice and human
HD patients are unknown, it may be the result of a defect in
energy metabolism. Through improved overall energy metab-
olism, CoQ10 may alter weight changes in the R6/2 mouse.
Examination of neuropathological sequela in the R6/2
mouse reveals several alterations that occur, such as
decreases in both brain volume and striatal neuron area
[10,13]. Treatment with minocycline, CoQ10 or the com-
bined minocycline/CoQ10 significantly attenuates brain
volume and striatal neuronal area loss in untreated R6/2
mice. This is, however, the first report to demonstrate
significant improvement in R6/2 neuropathology after
minocycline or the combined minocycline/CoQ10 treatment.
Further analysis of mutant htt aggregation confirms that
CoQ10 markedly ameliorated htt aggregation, while minocy-
cline had no effect on htt aggregation [13,14]. Analysis ofthe minocycline/CoQ10 combination demonstrates a marked
reduction in htt aggregation, suggesting that this aspect of
neuropathological improvement is mediated predominantly
by CoQ10.
Another prominent aspect of neuropathology observed in
R6/2 mice and human HD is an increase in reactive microglia
[10,28]. While CoQ10 treatment had no effect on reactive
microgliosis in R6/2 mice, minocycline markedly reduced
reactive microgliosis. Minocycline’s ability to reduce micro-
glial proliferation associated with neurodegeneration is consis-
tent with previously reported findings [20,29,30]. Furthermore,
the combined minocycline/CoQ10 also reduced the increase in
reactive microglia observed in R6/2 mice. Contrasted against
the inability of CoQ10 treatment to alter the microglial
response, this suggests that the attenuation of the microglial
response observed after the combinatorial therapy is most
likely the result of minocycline.
Given the complexities that underlie the pathogenesis of
HD, a therapeutic strategy that employs combined treatments
that target separate pathologies is likely to provide the most
beneficial improvement. The fact that both compounds have
already been safely assessed in HD patients, suggests their
combined use may provide potential added benefit.
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